Oppenheimer Keeps Their Hold Rating on CVS Health (CVS)
Oppenheimer analyst reiterated a Hold rating on CVS Health on February 11. The company’s shares closed yesterday at $77.02.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $96.24, which is a 24.95% upside from current levels. In a report released on February 11, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $77.00 price target.
Based on CVS Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $105.69 billion and a net profit of $2.94 billion. In comparison, last year the company earned a revenue of $97.71 billion and had a net profit of $1.64 billion
Read More on CVS:
Disclaimer & DisclosureReport an Issue
- MSFT Stock in the Spotlight as Microsoft Builds Its Own AI Model and Targets Healthcare
- Buy Rating Maintained on CVS: Credible Path to Profit Growth Despite 2027 MA Headwinds and Conservative 2026 Outlook
- CVS Health Earnings Call: Cash, Growth And Cost Risks
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Midday Fly By: Coca-Cola reports Q4 beat, BP suspends buyback
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.